A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
- Disease/Condition
- Lung Cancer
- Drug/Device/Intervention
- Tafolecimab
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Jinghui Wang
- Funder
- Beijing Chest Hospital, Capital Medical University
- Location
- Beijing, China
- Phase
- Phase 2
- Start date
- May 17, 2024
- End date
- May 30, 2027
- Enrollment
- 30 participants
PFS
The second-line treatment for patients who have progressed after first-line immune checkpoint
 inhibitor therapy, is chemotherapy based on docetaxel and other drugs. The treatment effect
 is limited. The median survival time of them are 6 months. So there is a huge unmet medical
 need.
 
 This study is a Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and
 Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or
 Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line
 Immunotherapy. 30 patients will be enrolled.
 
 The main endpoint is PFS，and the secondary endpoint are OS,DCR,DOR,ORR, and so on.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06421298
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06421298 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jinghui Wang and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.